Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \quad Origin: Appendix 5 \quad Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13 \\$ 

f entity	
lian Mines Limited (the <b>Compa</b>	any)
914 191	
ne entity) give ASX the following	g information.
<b>1 - All issues</b> st complete the relevant sections (attac	h sheets if there is not enough space).
*Class of *securities issued or to be issued	Ordinary fully paid shares ( <i>Ordinary Shares</i> )
Number of *securities issued or to be issued (if known) or maximum number which may be issued	Maximum number is 1 Ordinary Share (Share)
Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Ordinary Share
	dian Mines Limited (the Companies of the securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for price and dates

ooo38453.1 + See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

The Ordinary Share ranks *pari passu* with existing Ordinary Shares.

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

\$0.10

Yes

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) This Appendix 3B relates to the Second Supplementary Cleansing Prospectus issued 30 November 2018, the First Supplementary Cleansing Prospectus issued 14 September 2018 and the Original Prospectus dated 31 July 2018 (together, the Prospectus) and the Corporations Act requirement to apply for listing of securities under a Prospectus for a listed entity.

6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h *in* relation to the \*securities the subject of this Appendix 3B, and comply with section 6i

21 November 2018

6b The date the security holder resolution under rule 7.1A was passed

Nil – the share has not been issued or been agreed to be issued by the Company.

6c Number of \*securities issued without security holder approval under rule 7.1

#### 00038453.1

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	Nil	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	Nil	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	NA	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Nil under rule 7.1 (refe 281,218,395 under rule	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	February 2019 (or sucl	the Prospectus is 28 n other closing date as any supplementary or us to the Prospectus)
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	Number 2,812,183,950	+Class Ordinary fully paid
			<u> </u>

<sup>+</sup> See chapter 19 for defined terms.

+Class Number Number and +class of all 19,800,000 Bergen 9 \$0.0959 +securities not quoted on ASX year call options (including the \*securities in section 2 if applicable) Convertible 1,480,000 Securities with a face value of A\$1.00 each 669,000,000 \$0.12 SK Innovations call options exp. 31.12.2018 Dividend policy (in the case of a Not applicable 10 trust, distribution policy) on the increased capital (interests) Part 2 - Pro rata issue Is security holder approval 11 required? Is the issue renounceable or 12 non-renounceable? Ratio in which the +securities 13 will be offered \*Class of \*securities to which the 14 offer relates <sup>+</sup>Record date to determine 15 entitlements holdings on different 16 registers (or subregisters) be aggregated for calculating entitlements? Policy for deciding entitlements 17 in relation to fractions

000<u>38453.</u>1

<sup>+</sup> See chapter 19 for defined terms.

18	Names of countries in which the entity has security holders who will not be sent new offer documents
	Note: Security holders must be told how their entitlements are to be dealt with.
	Cross reference: rule 7.7.
19	Closing date for receipt of acceptances or renunciations
20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
25	If the issue is contingent on security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)

<sup>+</sup> See chapter 19 for defined terms.

30		do security holders sell entitlements <i>in full</i> through ker?	
31		1	
32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	
33	<sup>+</sup> Issue	e date	
	-	uotation of securities	
34	Type (tick o	of <sup>+</sup> securities one)	
(a)	X	<sup>+</sup> Securities described in Part	1
(b)		*	d of the escrowed period, partly paid securities that become fully paid n restriction ends, securities issued on expiry or conversion of convertible
Entiti	es tha	t have ticked box 34(a)	
Addit	tional	securities forming a new	class of securities
Tick to docum		e you are providing the informati	on or
35			securities, the names of the 20 largest holders of the ne number and percentage of additional <sup>+</sup> securities
36			securities, a distribution schedule of the additiona mber of holders in the categories
000384	53.1		

<sup>+</sup> See chapter 19 for defined terms.

37		A copy of any trust deed for the additional *securities
----	--	---

<sup>+</sup> See chapter 19 for defined terms.

Entitie	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and <sup>+</sup> class of all	Number	+Class
•	*securities quoted on ASX (including the *securities in clause 38)		

<sup>+</sup> See chapter 19 for defined terms.

### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Benjamin Bell Date: 30 November 2018 (Director)

Print name: Benjamin Bell

== == == ==

00038453.1

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	2,608,253,672	
<ul> <li>Add the following:         <ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul> </li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate</li> </ul> </li> </ul>	69,550,000 – issued 28 November 2017 16,811,916 - issued 5 July 2018 6,101,695 – issued 11 September 2018 14,800,000 – issued 14 September 2018 96,666,667 – issued 23 November 2018	
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	Nil	
"A"	2,812,183,950	

### 00038453.1

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
<b>Multiply</b> "A" by 0.15	421,827,593	
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1	
<ul> <li>Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:         <ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	421,827,593 securities on the basis that conversion of all of the convertible securities agreed to be issued by the Company, details of which were announced to the market on 11 September 2018, is subject to a maximum conversion limit equal to the Company's existing placement capacity as at the date of the Convertible Securities Subscription Agreement (absent shareholder approval).	
"C"	421,827,593	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15 Note: number must be same as shown in Step 2	421,827,593	
Subtract "C"  Note: number must be same as shown in Step 3	421,827,593	

**Total** ["A" x 0.15] – "C"

04/03/2013 Appendix 3B Page 11

Nil

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	2,812,183,950	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	281,218,395	
Step 3: Calculate "E", the amount of 7.1A that has already been used  Insert number of +equity securities issued or agreed to be issued in that 12 month	of placement capacity under rule  Nil	
period under rule 7.1A		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> </ul>		
<ul> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate</li> </ul>		
<ul> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of</li> </ul>	nil	

00038453.1

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	281,218,395	
Note: number must be same as shown in Step 2		
Subtract "E"	Nil	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	281,218,395	

<sup>+</sup> See chapter 19 for defined terms.